AZ withdraws cancer drug Lynparza from CDF evaluation

On the day that England's Cancer Drugs Fund (CDF) reduced the number of indications it will fund to 59 from 84, AstraZeneca (AZ) announced that it had withdrawn its ovarian cancer drug Lynp